Active ingredients: idelalisib
What it is used for
ZYDELIG in combination with rituximab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) upon relapse in patients for whom chemo-immunotherapy is not considered suitable. ZYDELIG in combination with ofatumumab is indicated for the treatment of adult patients with CLL/SLL upon relapse in patients for whom chemo-immunotherapy is not considered suitable. ZYDELIG is indicated as monotherapy for the treatment of patients with follicular lymphoma which is refractory to at least two prior systemic therapies. The disease must be refractory to both rituximab and an alkylating agent.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Oral
- Store below 30 degrees Celsius
- Store at room temperature
- Lifetime is 60 Months.
Always read the label. If symptoms persist see your healthcare professional.
Each 100 mg ZYDELIG tablet is oval-shaped, film-coated and orange in colour. Each tablet is debossed with GSI on one side and 100 on the other.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient idelalisib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf)